ArticleScientific reports2026
Next-generation platelet concentrate: Alb-PRF outperformed PRP and H-PRF in promoting endothelial function and wound healing.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Angiogenesis underpins regenerative success and refined autologous platelet concentrates (APCs) are therefore under continual optimization. This study compared optimized thermally-induced albumin hydrogel cross-linked with horizontally centrifuged platelet-rich fibrin (Alb-PRF) against traditional platelet-rich plasma (PRP) and standardized horizontal PRF (H-PRF). Alb-PRF was generated using specific centrifugation protocols. Each APC was co-cultured with human umbilical vein endothelial cells (HUVECs) respectively. Live/dead assay confirmed universal biocompatibility and safety, showing no significant differences in apoptosis among all groups. Additoinally, viability assay revealed possibly superior proliferation by Alb-PRF compared to PRP and H-PRF. Immunofluorescent cytoskeleton and morphology staining showed enhanced proliferative effects with Alb-PRF. Moreover, Alb-PRF significantly increased cell migration. Notably, LPS-induced inflammatory damage led to more apoptotic HUVECs in PRP and H-PRF groups, whereas Alb-PRF rescued this damage. Alb-PRF conferred cytoprotection and upregulated expression of CD31, suggesting an augmented vascular regeneration capacity. Altogether, Alb-PRF outperformed PRP and H-PRF in driving angiogenic potential under both normal and inflammatory conditions. Our findings underscore the translational promise of Alb-PRF, particularly as an innovative solution for wound healing in regenerative medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.